The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).
Lei Chen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Annie Guérin
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
Eric Q. Wu
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
Katherine Dea
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
Stuart L. Goldberg
Consultant or Advisory Role - ARIAD (U); Bristol-Myers Squibb (U); Novartis
Honoraria - ARIAD; Bristol-Myers Squibb; Novartis
Research Funding - Novartis